ALFA Finder| Revenue growth | 36% YoY growth in Q4 FY26. |
|---|---|
| Margins | Q4 margins at 34.3%; long-term sustainable range guided at 26-28%. |
| Order book | CRAMS projects in Europe and Japan moving to commercial trial stage. |
| Demand visibility | Slow recovery in Europe; customers placing smaller, frequent orders. |
| Management confidence | High confidence in long-term structural strength despite challenging macro environment. |
Growth
Q4 FY26 revenue grew 36% YoY and 57% QoQ; EBITDA grew 15% YoY; PAT declined 5% YoY to INR 6.27 cr.
Outlook
Block-7 commercial production starts Q2 FY27; CRAMS projects transitioning to commercial trials; sustainable EBITDA margins targeted at 26-28%.
Risks
Geopolitical volatility, fluctuating raw material prices, and regulatory approval delays in Europe and Japan.
Earnings Call filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹624.30
- Market cap
- ₹801.5 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 66.2×Sector 43.8×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
Shree Ganesh Remedies Results Update
Shree Ganesh Remedies released a press release on Q2 and H1 FY27 unaudited results, with Q2 revenue of ₹23.29 Crore, down 23% year-on-year. PAT fell 67% to ₹1.63 Crore.
Shree Ganesh Remedies Q2 FY27 Results: Net Profit ₹1.6 Cr, Down 68.0% YoY
Shree Ganesh Remedies' board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Revenue from operations for the half year was Rs 3,765.47 lakhs, down from Rs 5,498.29 lakhs a year earlier.
- Key figure
- Net profit ₹1.6 Cr · -68.0% YoY
Shree Ganesh Remedies Board Meeting Date
Shree Ganesh Remedies Ltd notified BSE of a board meeting on October 31, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 2026. Trading window remains closed until 48 hours after the results declaration.
Shree Ganesh Remedies Other Announcement
Shree Ganesh Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Shree Ganesh Remedies Management Change
Shree Ganesh Remedies Ltd has announced the resignation of Mr. Aditya Vikrambhai Patel as Company Secretary and the appointment of Ms. Akanksha as his successor.